Kusajili – Centralise les essais cliniques mondiaux

Résultat de votre recherche par promoteur : Johnson & Johnson Pharamceutical Resarch & Development, L.L.C

Femme et Homme Max 99 ans
Johnson & Johnson Pharamceutical Resarch & Development, L.L.C MAJ Il y a 4 ans

A One-Year, Randomized, Open-Label, Parallel-Arm, Phase III Long-Term Safety Trial, with Controlled Adjustment of Dose, of Multiple Doses of CG5503 PR* and Oxycodone CR in Subjects with Chronic Pain The primary objective of the trial is the evaluation of the safety profile of CG5503 PR base at doses ranging between 100 mg and 250 mg BID over long term exposure of up to one year.

Pays Aucun
Organes Aucun
Spécialités Aucune

Essai clos aux inclusions

Plus d'informations